Home > Healthcare > Medical Devices > Diagnostic Devices > Central Nervous System Biomarkers Market

Central Nervous System Biomarkers Market Size

Report ID: GMI8335
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Central Nervous System Biomarkers Market Size

Central Nervous System Biomarkers Market size was valued at USD 5.6 billion in 2023 and is estimated to grow at a CAGR of 8.1% between 2024 and 2032. Central nervous system (CNS) biomarkers refer to measurable substances or indicators found in biological samples that provide information about the status of the CNS.

To get key market trends

Download Free Sample

These biomarkers can include various molecules, proteins, genes, or other characteristics that are associated with normal CNS function or with the presence, progression, or severity of CNS related diseases. The increasing prevalence of neurological disorders have emerged as a significant driver for the market. For instance, according to the World Federation of Neurology, in 2023, over 40% of the global population is currently suffering from some kind of neurological condition, and this burden is projected to nearly double by 2050.

Furthermore, advancements in the biomarker discovery outsourcing services industry, which is estimated to reach USD 33.7 billion by 2032, are expected to contribute to the CNS biomarkers market growth. These include technological innovations, government initiatives and policies, increasing use of CNS biomarkers, and growing adoption of neurostimulation devices.

Central Nervous System Biomarkers Market Report Attributes
Report Attribute	Details
Base Year:	2023
Central Nervous System Biomarkers Market Size in 2023:	USD 5.6 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	8.1%
2032 Value Projection:	USD 11.3 Billion
Historical Data for:	2018 - 2023
No. of Pages:	160
Tables, Charts & Figures:	215
Segments covered:	Biomarker Type, Application, End-use, and Region
Growth Drivers:	Rising prevalence of neurological disorders Increasing advancements in biomarker discovery technologies Rising government initiatives and policies Increasing use of CNS biomarkers
Pitfalls & Challenges:	High cost associated with CNS biomarker tests and diagnostics Stringent regulatory scenario

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Central nervous system biomarkers market size was USD 5.6 billion in 2023 and is expected to register 8.1% CAGR from 2024-2032 owing to the increasing prevalence of neurological disorders worldwide.

The safety biomarker segment recorded USD 2.5 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their significance in clinical trials to monitor and assess the safety profile of new drugs.

North America central nervous system biomarkers industry reached USD 2.3 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of the world's leading research institutions focused on neuroscience and biomarker development in the region.

F. Hoffmann-La Roche Ltd, G-Biosciences, Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., Novartis AG, PerkinElmer Inc., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc., are some of the major central nervous system biomarkers companies worldwide.